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Enhanced fibrinolysis caused by tissue plasminogen activator release in
hemodialysis. The effect of hemodialysis on components of the fibrino-
lytic system was measured in 22 patients. Plasma levels oft-PA antigen,
t-PA activity, u-PA antigen and plasminogen activator inhibitor were
determined by means of immunological and functional assays. During
hemodialysis, II patients exhibited an increase in t-PA antigen within
the first hour to about three times the starting values (P < 0.05),
followed by a decrease to about double of the initial values until the end
of the treatment. Eleven patients showed a continuous increase up to
200% of the starting values until the end of hemodialysis. u-PA levels
did not change significantly during the time of investigation (P> 0.5).
There is evidence that during hemodialysis various plasmatic
enzyme systems like the contact phase components of the
coagulation cascade [lb the complement system [2, 31 and the
fibrinolytic system [41 can be activated. However, the mediator
of enhanced fibrinolytic activity during hemodialysis as re-
vealed by global assay systems, such as euglobulin, clot lysis
time is unknown; removal of inhibitory toxins by hemodialysis
[4] or plasminogen activator release into the circulation [4] are
discussed as possible explanations.
Tissue plasminogen activator (t-PA) is considered to be the
major activator of blood fibrinolysis. It is synthetized and
stored in endothelial cells, from where it can be released into
the blood stream. Several stimuli for t-PA release are known,
such as physical exercise [5], venous occlusion [6], cardiopul-
monary bypass [7] and infusion of vasoactive drugs [8], acti-
vated protein C [9] or heparin [10], Urokinase (u-PA) was first
isolated from human urine where it is contained in high con-
centrations in its active form, but it is also found in human
plasma in its inactive single chain form. The biological role of
this plasmatic u-PA is not yet known. Recent evidence suggests
that the circulating single—chain prourokinase might participate
in the intrinsic, factor XII-dependent, pathway of plasminogen
activation [11]. A fast—acting plasminogen activator inhibitor
which was described recently [12] complexes t-PA and active
u-PA in the circulation. Under normal conditions almost no free
plasminogen activator activity is found in plasma, although
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mean values of 4.3 ng/ml t-PA 113] and 7.2 ng/ml u-PA [14] can
be detected using immunological test systems. In addition,
depending on the assay systems used, a mean inhibition of 1.0
to 3.0 IU t-PA/ml can be found in plasma [15]. Therefore,
alterations of plasma levels of these components are thought to
cause enhanced blood fibrinolytic activity.
Based on these considerations, it was the aim of the present
study to determine changes in plasma levels of t-PA, u-PA, and
PA-inhibitor during the course of hemodialysis in order to
attribute enhanced fibrinolytic activity to changes of these
components.
Methods
Patients and controls
The effect of hemodialysis on fibrinolytic parameters was
studied in 22 chronically uremic patients (13 males, 9 females)
between 17 and 65 years of age (46.6 13.0 years, mean SD)
undergoing four hours hemodialysis treatments three times a
week for several months (range: 5 to 63 months, 25.6 8.4
months, mean SD). Fifteen patients suffered from chronic
glomerulonephritis, six from chronic pyelonephritis and one
from diabetic glomerulosclerosis. A control group consisted of
10 chronically uremic patients (6 males, 4 females; 50.3 14.2
years of age, mean SD) undergoing hemodialysis as described
above. In this group the effect of the administration of heparin
alone not followed by hemodialysis was studied. The patients
investigated in this study were on similar medication including
regular transfusion therapy and intermittent use of drugs reduc-
ing the plasma levels of potassium and phosphate.
Dialysis treatments
All treatments were performed with Prima-H cuprophane
dialyzers (Bellco S.p.A., Italy). Dialyzers were used only once.
The capillary filters were washed with 2 liters of 0.15 M NaCl
solution before the whole system was filled and hemodialysis
was started. In all cases dialysis was performed by an arterio-
venous Cimino-fistula on the forearm. Constant body weight
during the first 220 minutes of hemodialysis was achieved by
minimizing ultrafiltration with lowering outflow resistance.
Therefore, hematocrit values were in the same range before and
220 minutes after starting hemodialysis (24 4.3% vs. 26
3.8%, mean SD). All patients received a bolus of 3000 IU of
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Table 1. Mean values and standard deviations of fibrinolytic parameters for 22 patients during hemodialysis
Minutes of hemodialysis
0 lO_60a 120 180 220
t-PA antigen ng/ml 4.99 3.68 9.96 7.12" 7.79 4•97b 8.46 573b 8.99 6.34"
t-PA activity lU/mi <0.05 0.86 0.31" <0.05 <0.05 <0.05
PA inhibitor JUt-PA inhibited/mi 1.07 0.47 0.38 0.33" 0.58 0.4" 0.75 0.38" 0.82 0.38
u-PA antigen ng/ml 7.2 0.54 7.4 0.46 7.5 0.45 7.7 0.5 7.8 0.48
a Peak values measured within the time indicated
" Significant changes during the course of hemodialysis (P < 0.05, analysis of variance)
heparin (Liquemin "Roche") into the fistula immediately be-
fore the treatment was started. The control group received a
bolus of 3000 IU of heparin (Liquemin "Roche") intravenously
on a day off hemodialysis.
Plasma samples
Immediately before administration of heparin, predialysis
blood samples were drawn from the arteriovenous fistula before
the patients were connected to the dialysis system. Subse-
quently, samples were obtained from the arterial line of the
dialyzer at 10, 30, 60, 90, 120, 180 and 220 minutes after the
initiation of the hemodialysis treatment. In the control group
blood was taken before, 30 minutes and 60 minutes after the
application of heparin. Blood for measurement of t-PA antigen,
t-PA function, PA-inhibitor, u-PA antigen and hematocrit was
drawn into plastic tubes containing potassium EDTA (10 mM
final concentration). Plasma samples were obtained by imme-
diate centrifugation at 2000 x g for 15 minutes and stored in
polystyrene tubes at —70°C for up to four weeks until assayed.
Assay system for t-PA antigen
t-PA antigen was determined by means of an enzyme—linked
immunosorbent assay (ELISA) as described previously [13].
The normal range of t-PA antigen as determined from 36 healthy
volunteers (19 males, 17 females) between 41 and 60 years of
age (53.4 8.2 years, mean SD) was 4.3 2.7 ng/ml (mean
SD). The inter- and intraassay coefficients of variation in this
assay were 11.6% and 4.7%, respectively.
Assay system for t-PA activity
t-PA activity was determined by an indirect spectrophoto-
metric assay after immobilization of t-PA by a monoconal
antibody, which does not interfere with t-PA function [16].
Briefly, 96-well flat bottom polystyrene plates were coated with
monoclonal (murine) anti-t-PA 1gM (MPW1VPA, 10 g/ml, 12
hours, 4°C). After washing, either purified t-PA [17] for a
calibration curve or plasma samples were applied (12 hours,
4°C), Plasminogen activator activity of bound t-PA was quan-
tified using 0.3 .tM plasminogen [18], 100 g/mi CNBr fibrin-
ogen fragments [19] and 0.6 mri Val-Leu-Lys-pNA (S-2251;
Kabi, Sweden) as a plasmin substrate. After incubation for five
hours at 25°C absorbances were read at 405 nm. Linear
dose—response curves were obtained between 0.05 IU and 5 IU
t-PA/ml. In healthy resting volunteers plasma levels of t-PA
activity were always found to be below 0.05 lU/mI. The inter-
and intraassay coefficients of variation were 14.8% and 7.9%,
respectively.
Assay system for PA-inhibitor
PA-inhibitor was determined by titration of PA-inhibitor
containing plasma samples with immobilized purified t-PA and
quantifying the residual t-PA activity [16]. Briefly, 96-well flat
bottom polystyrene plates were coated with a monoclonal
(murine) anti-t-PA 1gM (MPWIVPA, 10 jgIml, 12 hours, 4°C).
In a second step purified t-PA 117] was applied (0.125 to 2
lU/mi, 12 hours, 4°C). After washing, either buffer or plasma
samples were applied (10 minutes, 25°C). Residual t-PA activity
was quantified using 0.3 M plasminogen [181, 100 p.g/ml CNBr
fibrinogen fragments [19] and 0.6 m Val-Leu-Lys-pNA
(S-225l, Kabi, Sweden). After incubation for five hours at 25°C
absorbances were read at 405 nm. The normal range of PA-
inhibitor as determined from 20 healthy volunteers (9 females,
11 males) between 40 and 60 years of age (51.4 6.7, mean
SD) was 1.09 0.15 IU/ml (mean SD). The inter- and
intraassay coefficients of variation were 11.5% and 9.4%, re-
spectively. The values found with this assay correlated with PA
inhibitor determinations performed by an indirect spectropho-
tometric assay which was developed previously in our labora-
tory [15].
Assay system for u-PA antigen
u-PA antigen was determined by means of a competitive
radioimmunoassay as described previously [141. The normal
range of u-PA antigen as determined from 155 healthy volun-
teers (85 females and 70 males) between 51 and 60 years of age
(53.0 3.1 years, mean SD) was 7.4 0.7 ng/ml (mean SD)
[20]. The inter- and intraassay coefficients of variation were
5.3% and 2.8%, respectively.
Significant differences for each parameter during the course
of hemodialysis were evaluated by analysis of variance, be-
tween different time points by Student's t-test for paired obser-
vations and between patients and normal controls by Student's
t-test for unpaired observations. Significance was assigned to P
values lower than 0.05.
Results
As shown in Table 1, plasma levels of t-PA antigen, t-PA
activity and PA inhibitor showed significant changes in the
course of hemodialysis treatments, whereas u-PA levels re-
mained almost unchanged.
Predialysis levels of t-PA antigen ranged from 1 to 14 ng/ml
(4.99 3.75 ng/ml, mean SD) and thus were not significantly
different from values obtained in normal controls. We found,
however, marked differences in individual responses to the
unknown stimulus for t-PA release during hemodialysis (Table
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Table 2. Individual t-PA levels in nglml for 22 patients
during hemodialysis
Patient Sex
Age
(years)
Minutes of hemodialysis Renal
disease0 60 120 180 220
1 F 55 4.0 15.2 6.9 7.4 8.1 GN
2 F 48 3.4 8.2 7.4 7.2 7.2 GN
3 M 43 2.2 3.0 3.6 4.0 4.4 PN
4 M 17 1.0 5.7 3.1 2.9 2.9 GN
5 F 24 5.6 5.8 5.8 6.4 7.2 PN
6 F 42 3.4 5.4 6.0 6.4 7.2 GN
7 F 50 5.4 6.2 7.2 7.5 8.0 ON
8 M 65 11.8 32.8 24.4 26.0 25.4 GN
9 M 54 3.6 4.0 4.0 4.2 3.8 ON
10 F 30 1.7 3.3 6.0 6.0 6.4 GN
11 F 43 2.2 11.6 10.4 10.8 10.8 PN
12 F 25 1.5 15.8 4.4 4.3 4.2 ON
13 M 48 4.6 5.6 6.0 6.0 6.2 GN
14 M 58 7.2 19.6 7.6 11.0 12.8 UN
15 F 43 1,5 5.6 1.8 1.7 2.0 ON
16 M 65 10.8 11.2 11.0 11.2 12.0 PN
17 M 49 1.9 7.6 7.0 6.0 5.0 DOS
18 M 35 1.6 3.5 2.8 2.0 1.6 ON
19 M 63 9.0 10.6 10.8 15.8 16.0 GN
20 M 38 6.8 10.0 12.0 12.6 13.4 ON
21 M 36 6.6 8.7 8.0 9.0 9.2 PN
22 M 63 14.0 19.8 15.4 17.8 24.0 PN
2). Patients 1, 2, 4, 8, 11, 12, 14, 15, 17, 18, 22 (denominated
group A) exhibited a significant peak level (about 300% of the
starting values) in t-PA antigen within the first hour of the
treatment. At the end of hemodialysis t-PA antigen levels still
measured up to 200% of the starting values in this group. The
remaining patients (denominated group B) exhibited a signifi-
cant but slow and continuous increase in t-PA antigen levels
during the treatment to nearly 200% of the predialysis values.
No significant increase in t-PA antigen was seen in the control
group after the application of heparin (before, 5.7 2.1 ng/ml;
30 mm after, 6.17 1.05 nglml; 60 mm after, 5.6 2.1 ng/ml).
Predialysis PA inhibitor levels were comparable with levels
obtained from normal controls, ranging from 0.4 to 2 IU/ml
(1.01 0.49 lU/mi, mean SD). Comparing the patients from
group A and group B, differences in pattern of PA inhibitor
levels during hemodialysis were found. A concomitant decrease
of PA inhibitor with the peak levels of t-PA antigen within the
first hour of the treatment was found in all members of group A
(Fig. I). PA inhibitor levels dropped to undetectable values
within the first hour of the treatment and were still reduced at
the end of hemodialysis in 6 of 11 patients from group A. In
these cases considerable amounts of free t-PA activity were
detected in plasma within the first hour of the treatment. In
group B, there was no significant decrease of PA inhibitor
during hemodialysis (data not shown).
Predialysis levels of u-PA antigen ranged from 6.8 to 7.9
ng/mI (7.2 0.54 ng/mi, mean SD) and thus were not
significantly different from values obtained in normal controls.
During hemodialysis, no significant changes in u-PA antigen
levels were found (P > 0.05).
Discussion
Significant changes in plasma levels of t-PA antigen, t-PA
activity and PA inhibitor during hemodialysis were found. On
Fig. 1. Pattern of t-PA antigen () and PA inhibitor (•) during
hemodialysis in ii patients exhibiting a peak t-PA release (group A).
Mean values SEM.
the other hand, plasma u-PA levels remained almost constant.
Therefore, it is likely that a release of t-PA from its site of
origin, the endothelial cells, occurs during hemodialysis and
causes the reported enhanced fibrinolytic activity [4]. Although
t-PA release exceeded the plasmatic PA inhibitor capacity in
some patients and free t-PA activity could be detected in blood,
the release of t-PA induced by hemodialysis is weak compared
to the release observed after infusion of DDAVP or after
venous occlusion where mean levels of about 20 nglml t-PA
antigen can be found [13]. Therefore, it is likely that during
hemodialysis no signs of a general activation of fibrinolysis and
thus no bleeding tendency can be detected. It was not surprising
to find marked individual differences in the extent of t-PA
release during hemodialysis as this phenomenon is also known
from investigations on other stimuli for t-PA release, like
venous occlusion [131 or physical exercise [21]. The decrease of
PA! levels in patients of group A is likely to be due to complex
formation with t-PA during the reported release reaction of the
activator within the first hour of hemodialysis, as reduced PA!
levels were only found concomitant with t-PA release. The slow
increase in t-PA antigen levels in patients of group B was
obviously balanced by the inhibition system, as PA! levels
remained constant. No relation was found between the patient's
disease or the frequency of treatment—induced symptoms like
hypotension or chest pain, and the changes in fibrinolysis
during hemodialysis. The predialysis t-PA antigen levels, how-
ever, were found to correlate with the age of the patients as it
was reported earlier for healthy individuals [13].
To explain the mechanisms which lead to t-PA release,
several phenomena known to be associated with hemodialysis
must be considered. There is a decrease in the leukocyte count
at the beginning of the hernodialysis treatment, which is accom-
panied by a release of several leukocyte proteases [22]. As it
was shown by Craddock et a! [2], the cause of this transient
leukopenia is leukostasis in the lung capillary system. Injury of
lung capillary endothelial cells by leukocyte proteases may lead
to t-PA release from these cells. Craddock et a! [2] also found a
decrease in arterial P02 within the first 30 minutes of hemodi-
alysis and explained it by a decreased diffusion efficiency of
oxygen and a decrement of pulmonary diffusing capacity, due to
leukostasis in the lung capillary system. Other investigators
attributed hypoxia during hemodialysis to hypoventilation, in-
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creased oxygen consumption, changes of 02-hemoglobin disso-
ciation or methods of dialysate delivery [23, 24]. It is known
that hypoxia is a stimulus for t-PA release into the circulation
[251.
Activation of the beta-adrenergic nervous system is also
known as a stimulus for systemic t-PA release [26]. A certain
kind of stress reaction at the beginning of the treatment could be
responsible for the activation of the fibrinolytic system. Con-
stant blood pressure and heart rate in almost all our patients
within the first hour of treatment make this explanation rather
unlikely. Complement activation at the beginning of hemodial-
ysis was shown by several investigators [2, 31 which in turn
could be associated with t-PA release. Vasoactive peptides
known to cause t-PA release [27] and generated in the course of
complement activation could be the link between these two
phenomena. Platelet activation in the artificial kidney [28] with
subsequent release of substances which are capable of inducing
a release oft-PA from the vessel wall, such as PAF acether [29],
must also be considered. As the application of heparin was
reported to cause an increase in plasma t-PA antigen levels [10],
control investigations were performed to rule out a connection
between the anticoagulant and the t-PA release during
extracorporal circulation. On a day off hemodialysis, no signif-
icant increase in t-PA antigen levels was detected in 10 chron-
ically uremic patients given the same dose of heparin as used in
hemodialysis treatments. The negative finding reported here
might reflect a dependence of heparin effects on dosage, route
of application and type of heparin. We conclude that the
observed increase in plasma t-PA antigen levels during hemo-
dialysis is due to effects of extracorporal circulation on the
fibrinolytic system.
From the data shown, t-PA release and consequent consump-
tion of PA inhibitor is likely to be the cause of enhanced
fibrinolytic activity during hemodialysis. However, it remains
unclear which of the possible stimuli alone or in combination
are responsible for this release reaction. Since the changes in
fibrinolytic activity observed during hemodialysis are now
defined, further studies on the causal relationship between
other effects of hemodialysis and t-PA release can be per-
formed.
Acknowledgments
This work was supported in part by the Austrian Fund for the
Promotion of Scientific Research P5654. The technical assistance of
Mrs. Irene Resch is thankfully acknowledged.
Reprint requests to Dr. W. Speiser, Laboraiory for Clini-
cal—Experimental Physiology, Department of Medical Physiology, Uni-
versity of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria,
References
1. WARDLE EN, PIERCY DA: Studies of contact activation of blood in
hemodialysis. J Clin Patho/ 25:1045—1049, 1972
2. CEADDOCX PR, FEHR J, BRIGHAM KL, KRONENBERG RS, JACOB
HS: Complement and leukocyte mediated pulmonary dysfunction
in hemodialysis. N Engi J Med 296:769—744, 1977
3. HAKIM RM, BREILLATT J, LAZARUS JM, PORT FK: Complement
activation and hypersensitivity reactions to dialysis membranes. N
Engi J Med 311:878—882, 1984
4. Kuttz H, LERNER R: Changes in fibrinolytic activity during the
course of a single hemodialysis session. Clin Nephrol 24:1—4, 1985
5. MARSH N, GAFFNEY P: Some observations on the release of
extrinsic and intrinsic plasminogen activators during exercise in
man. Haemostasis 9:238—247, 1980
6. CLARKE RL, ORANDI A, CLIFFTON EE: Induction of fibrinolysis by
venous obstruction. Angiology 11:367—370, 1960
7. STIBBE J, KLUFT C, BROMMER EJP, GOMES M, DE JONG DS,
NAUTA J: Enhanced fibrinolytic activity during cardiopulmonary
bypass in open heart surgery in man is caused by extrinsic
(tissue—type) plasminogen activator. Eur J C/in invest 14:375—382,
1984
8. MANUCCI PM, ROTA L: Plasminogen activator response after
DDAVP: A clinico-pharmacological study. Thromb Res 20:69—76,
1980
9. COMP PC, ESMON CT: Generation of fibrinolytic activity by infu-
sion of activated protein C into dogs. J C/in Invest 68:1221—1228,
1981
10. FAREED J, WALENGA JM, HOPPENSTAEDT DA, MESSMORE HL:
Studies on the profibrinolytic actions of heparin and its fractions.
Sem Thrombos Haemostas 11:199—207, 1985
11. WIJNGAARDS G, KLUFT C, GROENEFELD E: Demonstration of
urokinase—related fibrinolytic activity in human plasma. Br J
Haematol 5 1:165—170, 1982
12. KRUITHOF EKO, TRAN—THANG C, RANSIJN A, BACHMANN F:
Demonstration of a fast—acting inhibitor of plasminogen activators
in human plasma. Blood 64:907—913, 1984
13. KORNINGER C, SPEISER W, WOJTA J, BINDER BR: Sandwich
ELISA for t-PA antigen employing a monoclonal antibody. Thromb
Res 41 :527—535, 1984
14. HUBER K, KIRCHHEIMER J, BINDER BR: Characterization of a
specific anti-human urokinase antibody. Development of a sensitive
competition radioimmunoassay for urokinase antigen. J Lab Cliii
Med 103:684-694, 1984
15. KORNINGER C, WAGNER 0, BINDER BR: Tissue plasminogen
activator inhibitor in human plasma: Development of a functional
assay system and demonstration of a correlating Mr = 50,000
antiactivator. J Lab C/in Med 105:718-724, 1985
16. WOJTA J, WAGNER 0, TURCU L, BINDER BR: Combined assay
system for t-PA antigen, t-PA function and t-PA inhibitor in plasma
samples using monoclonal anti-t-PA antibodies. (abstract) Thromb
Haemostas 54:217, 1986
17. BINDER BR, SPRAGG J, AUSTEN KF: Purification and characteriza-
tion of human vascular plasminogen activator derived from blood
vessel perfusates. J Biol Chem 254:1998—2003, 1979
18. DEUTSCH DG, MERTZ ET: Plasminogen. Purification from human
plasma by affinity chromatography. Science 170:1095—1096, 1970
19. NIEUWENHIUZEN W, VERHEIJEN JH, VERM0ND A, CHANG GTG:
Plasminogen activation by tissue activator is accelerated in the
presence of fibrinogen cyanogen bromide fragments FCB-2. Bio-
chim Biophys Acta 755:531—533, 1983
20. KIRCHHEIMER J, BINDER BR: Urokinase antigen in plasma: Age
and sex dependent variations. Thromb Res 36:643—646, 1984
21. CASH JD: The effect of moderate exercise on the fibrinolytic system
in normal young men and women. Br Med J 2:502—506, 1966
22. HORL WH, JOCHUM M, HEIDLAND A, FRITZ H: Release of
granulocyte proteinases during hemodialysis. Am J Nephrol
3:213—217, 1983
23. VAzIRI ND, WILSON A, MUKAI D, DARWISH R, RUTZ A, HYATT J,
MORENO C: Dialysis hypoxemia: Role of dialyzer membrane and
dialysate delivery system. Am J Med 77:828—833, 1984
24. VAZIRI ND: Dialysis—induced hypoxemia. mt j Artif Organs
5:8—10, 1982
25. TAPPY L, HAUERT J, BACHMANN F: Effects of hypoxia and
acidosis on vascular plasminogen activator release in the pig ear
perfusion system. Thromb Res 33:117—124, 1984
26. CASH JD, WOODFIELD DG, ALLAN AGE: Adrenergic mechanisms
in the systemic plasminogen activator release to adrenalin in man.
Br J Haematol 18:487—494, 1970
27. KLOCKING HP: Release of plasminogen activator by acetylcholine
from the isolated perfused pig ear. Thromb Res 16:261—264, 1979
28. HAKIM RM, SCHAFER Al: Platelet activation during hemodialysis.
Am J Med 78:575—580, 1985
29. EMEIS JJ, KLUFT C: PAF-acether—induced release of tissue type
plasminogen activator from vessel walls: Involvement of a
lipoxygenase pathway. (abstract) Haemostasis 14:92, 1984
